Related Experiment Video
Updated: Jun 8, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Epidemiology of cryptococcal infection in hospitalized children
Neha S Joshi1, Brian T Fisher, Priya A Prasad
1Department of General Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. joshin@email.chop.edu
Insights
Pediatric cryptococcal infections (CI) are rare but serious. Most cases occurred in immunocompromised children, not necessarily those with HIV, highlighting the need for broader diagnostic awareness.
Area of Science:
- Pediatric Infectious Diseases
- Mycology
- Epidemiology
Background:
- Cryptococcus neoformans causes opportunistic infections, primarily in adults with AIDS.
- While recognized in HIV-negative individuals, data on pediatric cryptococcal infection (CI) remains limited.
- This study addresses the knowledge gap regarding CI in pediatric populations.
Purpose of the Study:
- To investigate the epidemiology and management of cryptococcal infections in pediatric patients.
- To identify patient characteristics, underlying conditions, and treatment patterns for CI in children.
- To determine the outcomes of pediatric CI, including mortality rates.
Main Methods:
- Retrospective analysis of the Pediatric Health Information System database (2003-2008).
- Inclusion of pediatric inpatients (<19 years) diagnosed with cryptococcosis or cryptococcal meningitis (CM).
- Evaluation of underlying medical conditions, antifungal therapies, and hospital discharge disposition.
Main Results:
- 63 pediatric CI cases identified (6.2 per million hospitalizations).
- Most patients (63.5%) had underlying immunocompromising conditions; 21% were immunocompetent, 16% had HIV.
- Non-CNS cryptococcosis (62%) was more frequent than CM (38%); overall in-hospital mortality was 9.5%.
Conclusions:
- Pediatric cryptococcosis predominantly affects non-HIV-infected children, but often those with other immunocompromising conditions.
- Treatment for CM generally followed adult guidelines, unlike non-CM cases.
- Further research is needed to optimize management strategies for pediatric CI.
Background:
Cryptococcus neoformans is a common opportunistic infection in adults with acquired immunodeficiency syndrome (AIDS), but cryptococcal infection (CI) has also been recognized in HIV-negative patients. Despite the fact that many studies were conducted in adults, limited data exist for pediatric patients.
Methods:
The Pediatric Health Information System, a database containing administrative information from 42 United States children's hospitals, was used to identify children admitted for the treatment of CI between 2003 and 2008. All pediatric inpatients less than 19 years of age who received an ICD-9 code for cryptococcosis or cryptococcal meningitis (CM) were included. Data regarding presence of underlying medical conditions, antifungal therapies administered, and hospital discharge disposition were evaluated.
Results:
A total of 63 cases of CI were identified, for a CI admission frequency of 6.2 cases per million hospitalizations. Most patients (63.5%) had an underlying immunocompromising medical condition, whereas 21% were immunocompetent and 16% were infected with HIV. Cryptococcosis not involving the central nervous system was more common than CM (62% vs. 38%). Most patients received a combination of fluconazole, amphotericin, and flucytosine in their treatment regimen; however, 9 patients received no antifungal medications. The overall in-hospital case fatality rate was 9.5%.
Conclusions:
The majority of pediatric cryptococcosis occurred in non-HIV-infected patients. However, most patients had other immunocompromising medical conditions. Patients with CM usually received therapy in accordance with the Infectious Disease Society of America guidelines for adults, but patients with non-CM were more likely to receive therapies not supported by these guidelines.
Related Concept Videos
Cryptococcal Meningitis
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Fungal Phylum Microsporidia
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption